Develops and manufactures pharmaceutical products for psychiatry, neurology, oncology, cardiovascular, renal, digestive, and ophthalmology. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $2.2B would still be left in the vault — a solid cushion for hard times.
The market pays 16.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 13% a year on average.
There is $3.7B in the vault; even if every debt were paid off, $2.2B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.